Author: admin

“Parkinson’s Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson’s Disease Market.

The Parkinson’s Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Parkinson’s Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Parkinson’s Disease treatment therapies with a considerable amount of success over the years.

• Parkinson’s Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson’s Disease treatment

• Emerging Parkinson’s Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson’s Disease market in the coming years.

• In February 2025, AstraZeneca’s diabetes drug Bydureon (exenatide) did not slow the progression of motor symptoms in Parkinson’s disease during a Phase III trial. Led by University College London (UCL) in the UK, the Exenatide-PD3 trial (NCT04232969) aimed to assess the impact of the glucagon-like peptide 1 receptor agonist (GLP-1RA) on disease progression. However, results published in The Lancet revealed that the trial did not achieve its primary or secondary endpoints.

• In January 2025, BlueRock Therapeutics, a U.S.-based subsidiary of Bayer, has advanced bemdaneprocel, its investigational cell therapy for Parkinson’s disease, to Phase III trials following a Phase I study that demonstrated the treatment was well tolerated.

• In January 2025, BIAL has announced the completion of the full dose regimen for the first participant in the multicenter Phase II ACTIVATE trial of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase) for treating Parkinson’s disease (PD). This therapy is specifically being developed for PD patients with a glucocerebrosidase 1 (GBA1) gene mutation (GBA-PD). Designed for once-daily oral administration, BIA 28-6156 aims to restore sphingolipid recycling to address the underlying cause of PD.

• In December 2024, Belgian pharmaceutical company UCB decided to discontinue the development of minzasolmin for Parkinson’s disease after the ORCHESTRA study did not achieve its primary or secondary endpoints. In the ORCHESTRA proof-of-concept trial (NCT04658186), minzasolmin—an investigational oral small-molecule inhibitor targeting alpha-synuclein misfolding—failed to show superiority over placebo.

• In October 2024, Adaptive Research, a clinical trial site organization focused on making clinical trials more accessible, announced its involvement in a pioneering decentralized study for Parkinson’s Disease sponsored by PhotoPharmics Inc. The California Movement Disorders Center, part of Adaptive Research’s network, will be a site for PhotoPharmics’ LIGHT-PD trial, which aims to evaluate the effectiveness of Celeste® Specialized Phototherapy in treating Parkinson’s symptoms.

• In September 2024, AbbVie’s recently acquired Parkinson’s disease treatment, tavapadon, demonstrated a significant reduction in disease burden in a Phase III trial. The TEMPO-1 trial (NCT04201093) assessed two daily doses of tavapadon (5mg and 15mg) and successfully met its primary endpoint. Both dosage groups outperformed the placebo in reducing disease burden at week 26, as evaluated by a combined score from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).

Parkinson’s Disease Overview

Parkinson’s disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson’s disease experience difficulties with movement control.

Get a Free Sample PDF Report to know more about Parkinson’s Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights

Emerging Parkinson’s Disease Drugs Under Different Phases of Clinical Development Include:

• KM-819: FAScinate Therapeutics

• Prasinezumab: Hoffmann-La Roche

• P2B001: Pharma Two B Ltd.

• NPT1220-478: Neuropore Therapies, Inc.

• Dapansutrile: Olatec Therapeutics

• UCB7853: UCB Biopharma

• UB-312: Vaxxinity

• Emrusolmin: Modag

• PT320: Peptron

• KDT-3594: Kissei Pharmaceutical

• Tavapadon: Cerevel Therapeutics

Parkinson’s Disease Route of Administration

Parkinson’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Parkinson’s Disease Molecule Type

Parkinson’s Disease Products have been categorized under various Molecule types, such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Parkinson’s Disease Pipeline Therapeutics Assessment

• Parkinson’s Disease Assessment by Product Type

• Parkinson’s Disease By Stage and Product Type

• Parkinson’s Disease Assessment by Route of Administration

• Parkinson’s Disease By Stage and Route of Administration

• Parkinson’s Disease Assessment by Molecule Type

• Parkinson’s Disease by Stage and Molecule Type

DelveInsight’s Parkinson’s Disease Report covers around 150+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Parkinson’s Disease product details are provided in the report. Download the Parkinson’s Disease pipeline report to learn more about the emerging Parkinson’s Disease therapies

Some of the key companies in the Parkinson’s Disease Therapeutics Market include:

Key companies developing therapies for Parkinson’s Disease are – Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others.

Parkinson’s Disease Pipeline Analysis:

The Parkinson’s Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.

• Parkinson’s Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Parkinson’s Disease drugs and therapies

Parkinson’s Disease Pipeline Market Drivers

• Increasing prevalence of Parkinson’s Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson’s Disease Market.

Parkinson’s Disease Pipeline Market Barriers

• However, lack of awareness and delayed diagnosis, side effects associated with Parkinson’s disease treatment drugs and other factors are creating obstacles in the Parkinson’s Disease Market growth.

Scope of Parkinson’s Disease Pipeline Drug Insight

• Coverage: Global

• Key Parkinson’s Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others

• Key Parkinson’s Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others

• Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies

• Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers

Request for Sample PDF Report for Parkinson’s Disease Pipeline Assessment and clinical trials

Table of Contents

1. Parkinson’s Disease Report Introduction

2. Parkinson’s Disease Executive Summary

3. Parkinson’s Disease Overview

4. Parkinson’s Disease- Analytical Perspective In-depth Commercial Assessment

5. Parkinson’s Disease Pipeline Therapeutics

6. Parkinson’s Disease Late Stage Products (Phase II/III)

7. Parkinson’s Disease Mid Stage Products (Phase II)

8. Parkinson’s Disease Early Stage Products (Phase I)

9. Parkinson’s Disease Preclinical Stage Products

10. Parkinson’s Disease Therapeutics Assessment

11. Parkinson’s Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Parkinson’s Disease Key Companies

14. Parkinson’s Disease Key Products

15. Parkinson’s Disease Unmet Needs

16 . Parkinson’s Disease Market Drivers and Barriers

17. Parkinson’s Disease Future Perspectives and Conclusion

18. Parkinson’s Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amnea

DelveInsight’s “Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Parainfluenza Virus Infection, historical and forecasted epidemiology as well as the Parainfluenza Virus Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Parainfluenza Virus Infection, offering comprehensive insights into the Parainfluenza Virus Infection revenue trends, prevalence, and treatment landscape. The report delves into key Parainfluenza Virus Infection statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Parainfluenza Virus Infection therapies. Additionally, we cover the landscape of Parainfluenza Virus Infection clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Parainfluenza Virus Infection treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Parainfluenza Virus Infection space.

To Know in detail about the Parainfluenza Virus Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parainfluenza Virus Infection Market Forecast

Some of the key facts of the Parainfluenza Virus Infection Market Report:

• The Parainfluenza Virus Infection market size was valued ~USD 259 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In December 2024, Blue Lake Biotechnology, Inc., a clinical-stage company specializing in intranasal vaccines, announced positive preliminary results from its Phase 1/2a clinical study of BLB201, an intranasal RSV vaccine candidate. The analysis included the first 63 infants and young children enrolled in the trial. The company develops parainfluenza virus 5 (PIV5)-vectored vaccines designed to engage the full immune system for protection against severe infectious diseases.

• In November 2024, Blue Lake Biotechnology, Inc., a clinical-stage company specializing in intranasal vaccines using parainfluenza virus 5 (PIV5)-vectored technology to activate the full immune system for protection against serious infections, along with its affiliate CyanVac LLC, today announced results from a 227-participant Phase 2a clinical trial. The data demonstrate the safety, tolerability, immunogenicity, and efficacy of CVXGA, the company’s intranasal vaccine candidate for COVID-19.

• In 2023, the US held the largest market share in the 7MM, accounting for 68%, followed by EU4 and the UK, with growth expected throughout the forecast period (2024–2034).

• In 2023, EU4 and the UK accounted for approximately 23% of the total market share in the 7MM.

• Key Parainfluenza Virus Infection Companies: Ansun Biopharma, AlloVir, MedImmune LLC, and others

• Key Parainfluenza Virus Infection Therapies: DAS181, ALVR106, Oplunofusp, MEDI-534, and others

• The Parainfluenza Virus Infection market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parainfluenza Virus Infection pipeline products will significantly revolutionize the Parainfluenza Virus Infection market dynamics.

• DelveInsight estimates that there were 2,709,923 cases of parainfluenza virus infection in the 7MM in 2023.

• In 2023, the United States recorded 1,456,399 new cases of parainfluenza virus, with numbers expected to rise during the forecast period.

• According to estimates, the total number of incident cases of parainfluenza virus infection in EU4 and the UK was 991,115 in 2023. Among the EU4 countries, Spain reported the highest proportion of cases, while the UK had the fewest.

• Estimates indicate that Japan reported approximately 262,409 cases of parainfluenza virus infection in 2023, with numbers expected to rise by 2034.

Parainfluenza Virus Infection Overview

Parainfluenza virus infection is a respiratory illness caused by the parainfluenza viruses, which are part of the paramyxovirus family. These viruses primarily affect the upper and lower respiratory tract, leading to symptoms similar to the common cold, such as fever, cough, runny nose, and sore throat. In more severe cases, particularly in young children and individuals with weakened immune systems, parainfluenza virus infection can lead to conditions like croup, bronchitis, or pneumonia. The infection is highly contagious and spreads through respiratory droplets when an infected person coughs or sneezes. There is no specific antiviral treatment, but supportive care is typically provided to manage symptoms.

Get a Free sample for the Parainfluenza Virus Infection Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/parainfluenza-virus-infection-market

Parainfluenza Virus Infection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Parainfluenza Virus Infection Epidemiology Segmentation:

The Parainfluenza Virus Infection market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Parainfluenza Virus Infection

• Prevalent Cases of Parainfluenza Virus Infection by severity

• Gender-specific Prevalence of Parainfluenza Virus Infection

• Diagnosed Cases of Episodic and Chronic Parainfluenza Virus Infection

Download the report to understand which factors are driving Parainfluenza Virus Infection epidemiology trends @ Parainfluenza Virus Infection Epidemiology Forecast

Parainfluenza Virus Infection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parainfluenza Virus Infection market or expected to get launched during the study period. The analysis covers Parainfluenza Virus Infection market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Parainfluenza Virus Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Parainfluenza Virus Infection Therapies and Key Companies

• DAS181: Ansun Biopharma

• ALVR106: AlloVir

• Oplunofusp: Ansun Biopharma

• MEDI-534: MedImmune LLC

Discover more about therapies set to grab major Parainfluenza Virus Infection market share @ Parainfluenza Virus Infection Treatment Landscape

Parainfluenza Virus Infection Market Drivers

• Rising Incidence

• Advancements in Diagnostic Tools

• Growing Awareness

• Development of Vaccines

• Supportive Healthcare Policies

Parainfluenza Virus Infection Market Barriers

• Lack of Specific Treatments

• High R&D Costs

• Limited Awareness in Low-Income Regions

• Seasonal Variability

• Regulatory Challenges

Scope of the Parainfluenza Virus Infection Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Parainfluenza Virus Infection Companies: Ansun Biopharma, AlloVir, MedImmune LLC, and others

• Key Parainfluenza Virus Infection Therapies: DAS181, ALVR106, Oplunofusp, MEDI-534, and others

• Parainfluenza Virus Infection Therapeutic Assessment: Parainfluenza Virus Infection current marketed and Parainfluenza Virus Infection emerging therapies

• Parainfluenza Virus Infection Market Dynamics: Parainfluenza Virus Infection market drivers and Parainfluenza Virus Infection market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Parainfluenza Virus Infection Unmet Needs, KOL’s views, Analyst’s views, Parainfluenza Virus Infection Market Access and Reimbursement

To know more about Parainfluenza Virus Infection companies working in the treatment market, visit @ Parainfluenza Virus Infection Clinical Trials and Therapeutic Assessment

Table of Contents

1. Parainfluenza Virus Infection Market Report Introduction

2. Executive Summary for Parainfluenza Virus Infection

3. SWOT analysis of Parainfluenza Virus Infection

4. Parainfluenza Virus Infection Patient Share (%) Overview at a Glance

5. Parainfluenza Virus Infection Market Overview at a Glance

6. Parainfluenza Virus Infection Disease Background and Overview

7. Parainfluenza Virus Infection Epidemiology and Patient Population

8. Country-Specific Patient Population of Parainfluenza Virus Infection

9. Parainfluenza Virus Infection Current Treatment and Medical Practices

10. Parainfluenza Virus Infection Unmet Needs

11. Parainfluenza Virus Infection Emerging Therapies

12. Parainfluenza Virus Infection Market Outlook

13. Country-Wise Parainfluenza Virus Infection Market Analysis (2020–2034)

14. Parainfluenza Virus Infection Market Access and Reimbursement of Therapies

15. Parainfluenza Virus Infection Market Drivers

16. Parainfluenza Virus Infection Market Barriers

17. Parainfluenza Virus Infection Appendix

18. Parainfluenza Virus Infection Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parainfluenza Virus Infection Market to Expand Significantly by 2034, States DelveInsight Report | Ansun Biopharma, AlloVir, MedImmune

DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Fabry Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fabry Disease Market Forecast

Some of the key facts of the Fabry Disease Market Report:

• The Fabry Disease market size was valued ~USD 1,306 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In December 2024, Exegenesis Bio, a global clinical-stage gene therapy company, announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to EXG110, an innovative gene therapy for Fabry disease—a rare lysosomal disorder characterized by excessive lipid accumulation in tissues, leading to renal failure, cardiac complications, and strokes.

• In 2022, the U.S. had the largest Fabry Disease market size among the 7MM, valued at approximately USD 625 million, with projections for further growth by 2032

• Within the European Union, the United Kingdom and Italy represent the largest market shares, with figures reaching USD 158 million and USD 150 million respectively in 2022. Conversely, Spain holds the lowest market position during the same period, with a recorded figure of USD 44 million.

• In 2022, the Fabry Disease market size reached its peak in the US among the seven major markets (7MM), amounting to approximately USD 625 million. This figure is projected to continue rising through to 2032.

• In 2022, there were a total of 15,290 diagnosed prevalent cases of Fabry Disease in the seven major markets (7MM), with the highest number of cases recorded in the United States. The EU4 countries and the UK accounted for 5,245 cases, while Japan had 1,690 cases.

• In the US, 4,345 males and 4,011 females were affected by Fabry disease in 2022. These numbers are expected to rise by 2032.

• In 2022, the UK had the highest number of diagnosed prevalent cases of Fabry Disease among the EU4 and the UK, with approximately 58% of the cases being female and 42% male. These numbers are anticipated to change during the forecast period.

• DelveInsight analysts reported that the diagnosed prevalent cases of Fabry Disease in 2022 were categorized into classic and late-onset phenotypes. There were 3,342 cases of the classic phenotype and 5,013 cases of the late-onset phenotype in the seven major markets (7MM).

• Key Fabry Disease Companies: Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others

• Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST -920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others

• The Fabry Disease epidemiology based on gender analyzed that Fabry Disease is more prevalent in males than females in the United States

• The Fabry Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fabry Disease pipeline products will significantly revolutionize the Fabry Disease market dynamics.

Fabry Disease Overview

Fabry disease is a rare genetic disorder caused by mutations in the GLA gene, which leads to a deficiency or malfunction of the enzyme alpha-galactosidase A. This enzyme is crucial for breaking down a fatty substance called globotriaosylceramide (Gb3 or GL-3) in the body’s cells. When alpha-galactosidase A is deficient or dysfunctional, Gb3 accumulates in various tissues and organs, leading to a wide range of symptoms.

Get a Free sample for the Fabry Disease Market Report:

https://www.delveinsight.com/report-store/fabry-disease-market

Fabry Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fabry Disease Epidemiology Segmentation:

The Fabry Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Fabry Disease

• Prevalent Cases of Fabry Disease by severity

• Gender-specific Prevalence of Fabry Disease

• Diagnosed Cases of Episodic and Chronic Fabry Disease

Download the report to understand which factors are driving Fabry Disease epidemiology trends @ Fabry Disease Epidemiology Forecast

Fabry Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fabry Disease market or expected to get launched during the study period. The analysis covers Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fabry Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fabry Disease Therapies and Key Companies

• ELFABRIO (PRX-102): Chiesi and Protalix Biotherapeutics

• Venglustat: Sanofi Genzyme

• Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics

• PRX-102: Protalix Biotherapeutics

• AVR-RD-01: AVROBIO

• Venglustat: Sanofi Genzyme

• ST-920: Sangamo Therapeutics

• FLT190: Freeline Therapeutics

• 4D-310: 4D Molecular Therapeutics

• Lucerastat: Idorsia Pharmaceuticals

• Moss-aGal: Greenovation Biotech GMBH

• PRX-102: ICON plc

• pegunigalsidase alfa: Chiesi Farmaceutici S.p.A.

• migalastat: Amicus Therapeutics

• Agalsidase alfa: Shire

Discover more about therapies set to grab major Fabry Disease market share @ Fabry Disease Treatment Market

Fabry Disease Market Strengths

• Emphasis on NBS to detect Fabry Disease at an early stage allows for timely treatment with better risk- benefit assessment.

• The growing Fabry Disease pool is expected to propel the treatment market, adding opportunities for new pharma players.

Fabry Disease Market Opportunities

• Development of potential biomarkers allows tracking the severity and predicting the progression of the disease, as well as checking the effectiveness of therapeutic intervention.

• The shortcomings of enzyme replacement therapy, partly due to antibody formation, can be alleviated by combining new oral therapy approaches.

Scope of the Fabry Disease Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Fabry Disease Companies: Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others

• Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others

• Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies

• Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Fabry Disease Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement

To know more about Fabry Disease companies working in the treatment market, visit @ Fabry Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Fabry Disease Market Report Introduction

2. Executive Summary for Fabry Disease

3. SWOT analysis of Fabry Disease

4. Fabry Disease Patient Share (%) Overview at a Glance

5. Fabry Disease Market Overview at a Glance

6. Fabry Disease Disease Background and Overview

7. Fabry Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Fabry Disease

9. Fabry Disease Current Treatment and Medical Practices

10. Fabry Disease Unmet Needs

11. Fabry Disease Emerging Therapies

12. Fabry Disease Market Outlook

13. Country-Wise Fabry Disease Market Analysis (2019–2032)

14. Fabry Disease Market Access and Reimbursement of Therapies

15. Fabry Disease Market Drivers

16. Fabry Disease Market Barriers

17. Fabry Disease Appendix

18. Fabry Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics

DelveInsight’s “Achondroplasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Achondroplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Achondroplasia Market Forecast

Some of the key facts of the Achondroplasia Market Report:

• The Achondroplasia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In September 2024, BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic disorders, announced today that the FDA has granted Breakthrough Therapy Designation to oral infigratinib, which is being developed for pediatric achondroplasia. This designation aims to accelerate the development and regulatory review of drugs in the U.S. that meet strict criteria. To qualify, a drug must show initial clinical evidence of potentially significant improvement on clinically meaningful endpoints compared to existing treatments.

• In the United States, achondroplasia impacts a slightly higher percentage of females (51.2%) compared to males (48.8%). This slight difference may be attributed to genetic or biological factors that contribute to its somewhat greater prevalence in females.

• In 2023, the total number of diagnosed prevalent cases of achondroplasia in Japan and the US was approximately 18,000, with expectations for this number to increase in the coming years.

• In 2023, Japan had around 3,000 diagnosed prevalent cases of achondroplasia.

• The epidemiology model categorizes age-specific cases into nine groups: 0–4, 5–10, 11–15, 16–20, 21–30, 31–40, 41–50, 51–60, and over 60. DelveInsight’s estimates indicate that the 5–10 age group was the most affected in the US, with around 4,000 cases reported in 2023.

• Achondroplasia is estimated to occur in 1 out of every 15,000 to 40,000 live births, making it one of the most prevalent types of skeletal dysplasia.

• Key Achondroplasia Companies: BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others

• Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others

• The Achondroplasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Achondroplasia pipeline products will significantly revolutionize the Achondroplasia market dynamics.

Achondroplasia Overview

Achondroplasia is a genetic disorder and the most common form of dwarfism, characterized by abnormal bone growth that results in short stature with disproportionately short arms and legs, a larger head, and distinctive facial features. It is caused by mutations in the *FGFR3* gene, which affects cartilage formation and bone growth. This condition is typically inherited in an autosomal dominant pattern, meaning that only one copy of the altered gene is sufficient to cause the disorder. While people with achondroplasia often have normal intelligence and lifespan, they may experience certain health challenges such as spinal stenosis, ear infections, and respiratory issues.

Get a Free sample for the Achondroplasia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/fabry-disease-market

Achondroplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Achondroplasia Epidemiology Segmentation:

The Achondroplasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Achondroplasia

• Prevalent Cases of Achondroplasia by severity

• Gender-specific Prevalence of Achondroplasia

• Diagnosed Cases of Episodic and Chronic Achondroplasia

Download the report to understand which factors are driving Achondroplasia epidemiology trends @ Achondroplasia Epidemiology Forecast

Achondroplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Achondroplasia market or expected to get launched during the study period. The analysis covers Achondroplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Achondroplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Achondroplasia Therapies and Key Companies

• VOXZOGO (vosoritide): BioMarin Pharmaceuticals

• Infigratinib: BridgeBio/ QED Therapeutics

• RBM-007: Ribomic Inc

• Sanofi: SAR-442501

• Recombinant human growth hormone: Changchun GeneScience Pharma

• Infigratinib: QED Therapeutics, Inc.

• TransCon CNP: Ascendis Pharma A/S

• Infigratinib: QED Therapeutics, Inc

• vosoritide: BioMarin Pharmaceuticals

• BMN 111: BioMarin Pharmaceutical

Discover more about therapies set to grab major Achondroplasia market share @ Achondroplasia Treatment Landscape

Scope of the Achondroplasia Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Achondroplasia Companies: BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin Pharmaceuticals, BioMarin Pharmaceutical, and others

• Key Achondroplasia Therapies: VOXZOGO (vosoritide), Infigratinib, RBM-007, SAR-442501, Recombinant human growth hormone, Infigratinib, TransCon CNP, Infigratinib, vosoritide, BMN 111, and others

• Achondroplasia Therapeutic Assessment: Achondroplasia current marketed and Achondroplasia emerging therapies

• Achondroplasia Market Dynamics: Achondroplasia market drivers and Achondroplasia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Achondroplasia Unmet Needs, KOL’s views, Analyst’s views, Achondroplasia Market Access and Reimbursement

To know more about Achondroplasia companies working in the treatment market, visit @ Achondroplasia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Achondroplasia Market Report Introduction

2. Executive Summary for Achondroplasia

3. SWOT analysis of Achondroplasia

4. Achondroplasia Patient Share (%) Overview at a Glance

5. Achondroplasia Market Overview at a Glance

6. Achondroplasia Disease Background and Overview

7. Achondroplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Achondroplasia

9. Achondroplasia Current Treatment and Medical Practices

10. Achondroplasia Unmet Needs

11. Achondroplasia Emerging Therapies

12. Achondroplasia Market Outlook

13. Country-Wise Achondroplasia Market Analysis (2020–2034)

14. Achondroplasia Market Access and Reimbursement of Therapies

15. Achondroplasia Market Drivers

16. Achondroplasia Market Barriers

17. Achondroplasia Appendix

18. Achondroplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Achondroplasia Market on Track for Major Expansion by 2034, According to DelveInsight | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic Inc